title: Plasma perfusion in myasthenia gravis.
abstract: Seven patients with myasthenia gravis (MG) unresponsive to thymectomy and steroid treatment (Osserman group III) underwent plasma perfusion (PP). All patients showed palpebral ptosis, diplopia, dysphonia, dysphagia, and muscle weakness; five of them had impaired ventilatory function. Separated plasma was perfused onto a column to adsorb anti-AChR-Ab. Each patient received a treatment cycle of six PP sessions. Clinical conditions were assessed before and after the treatment, with evaluation of muscular strength, ventilatory function, and electromyographic testing (RSS). Immunologic markers were tested before and after each PP. Clinical improvement in bulbar symptoms and respiratory function was noted in all patients after one to three PP. Limb muscle strength began to improve later. Serum concentration decreased (mean % +/- SD) after each PP:anti-AChR-Ab 36.47 +/- 17.43; IgA 20.44 +/- 11.26; IgG 21.24 +/- 32.56; IgM 23.22 +/- 11.40; C3 36.78 +/- 10.15; C4 42.69 +/- 14.82. In five of seven patients the improvement continues (follow-up 1 to 10 months). In one patient it lasted only 1 month, and in another a relapse occurred after 10 months of benefit, but was successfully reversed by retreatment.
authors.affiliation: C.I. Columbus-Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Passalacqua
authors.forename: G
authors.initials: G
authors.lastname: Splendiani
authors.forename: A
authors.initials: A
authors.lastname: Sturniolo
authors.forename: S
authors.initials: S
authors.lastname: Costanzi
authors.forename: G
authors.initials: G
authors.lastname: Barbera
authors.forename: G
authors.initials: G
authors.lastname: D'Agostini
authors.forename: C
authors.initials: C
authors.lastname: Scoppetta
authors.forename: D
authors.initials: D
authors.lastname: Adorno
authors.forename: S
authors.initials: S
authors.lastname: DiGiulio
authors.forename: C
authors.initials: C
authors.lastname: Casciani
mesh_terms: D000328:Adult; D001323:Autoantibodies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000628:therapy*; D010477:Perfusion; D010956:Plasmapheresis / Q000379:methods*; D011950:Receptors, Cholinergic / Q000276:immunology; D013934:Thymectomy
chemical_list: D001323:Autoantibodies; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic